# US 2021/0260032 A1 · Composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260032 A1
- Document ID: US20210260032A1
- Status: Published application
- Kind: A1
- Application number: 17/261,548
- Filed: 2019-07-19
- Published: 2021-08-26
- Earliest claimed: 2018-07-20
- Applicants: Metaceutical Technologies Limited
- Inventors: Kenneth Benning
- Web page: https://patentgrep.com/patent/US20210260032A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 36/71: Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K 47/02: Inorganic compounds
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 39/02: Antidotes
- C01B 39/02: Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The invention relates to compositions comprising a chelating agent bound to an extended surface biologically inert substrate, methods of producing said compositions and uses of said compositions in treating heavy metal poisoning, as dietary supplements and as sports supplements.

## Claims

### Claim 1

1) A composition comprising a chelating agent bound to an extended surface biologically inert substrate.

### Claim 2 (depends on 1)

2) The composition according to claim 1, wherein the chelating agent is a heavy metal chelating agent.

### Claim 3 (depends on 1, 2)

3) The composition according to claim 1 or claim 2, wherein the chelating agent is melanin.

### Claim 4 (depends on 3)

4) The composition according to claim 3, wherein the melanin is natural melanin.

### Claim 5 (depends on 4)

5) The composition according to claim 4, wherein the natural melanin is a Nigella sativa L. melanin extract.

### Claim 6 (depends on 1, 2)

6) The composition according to claim 1 or claim 2, wherein the chelating agent is tannin.

### Claim 7 (depends on 6)

7) The composition according to claim 6, wherein the tannin is natural tannin.

### Claim 8 (depends on 7)

8) The composition according to claim 7, wherein the natural tannin is an extract from a nut, such as hazelnut, walnut or almond.

### Claim 9

9) The composition according to any one of the preceding claims, wherein the extended surface biologically inert substrate is a zeolite.

### Claim 10 (depends on 9)

10) The composition according to claim 9, wherein the zeolite is 13X zeolite.

### Claim 11 (depends on 9)

11) The composition according to claim 9, wherein the zeolite is clinoptinolite.

### Claim 12 (depends on 11)

12) The composition according to claim 11, wherein the clinoptinolite is crushed natural clinoptinolite.

### Claim 13 (depends on 11)

13) The composition according to claim 11, wherein the clinoptinolite is synthetic clinoptinolite.

### Claim 14

14) The composition according to any one of the preceding claims, wherein the chelating agent is bound directly to the extended surface biologically inert substrate.

### Claim 15

15) The composition according to any one of the preceding claims, wherein the chelating agent is integrated within the structure of the extended surface biologically inert substrate.

### Claim 16

16) The composition according to any one of the preceding claims, wherein the composition further comprises an adherent.

### Claim 17 (depends on 16)

17) The composition according to claim 16, wherein the adherent is Nafion.

### Claim 18 (depends on 16, 17)

18) The composition according to claim 16 or claim 17, wherein binding of the chelating agent to the extended surface biologically inert substrate is enhanced by the adherent.

### Claim 19

19) The composition according to any one of the preceding claims, wherein the composition is in dosage form.

### Claim 20

20) The composition according to any one of the preceding claims, wherein the composition is formulated for oral administration.

### Claim 21

21) The composition according to any one of the previous claims, wherein the composition is in the form of a capsule.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

22) The composition according to any one of claims 1 to 20, wherein the composition is in the form of a tablet.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

23) The composition according to any one of claims 1 to 20, wherein the composition is in the form of a powder.

### Claim 24 (depends on 19, 20, 21, 22, 23)

24) The composition according to any one of claims 19 to 23, further comprising a gastro-resistant coating.

### Claim 25 (depends on 19, 20, 21, 22, 23, 24)

25) The composition according to any one of claims 19 to 24, wherein the composition is a time-release formulation.

### Claim 26 (depends on 25)

26) The composition according to claim 25, wherein the composition is a time-release formulation in the form of a capsule.

### Claim 27 (depends on 19, 20, 21, 22, 23, 24, 25, 26)

27) The composition according to any one of claims 19 to 26, further comprising an antacid.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

28) The composition according to any one of claims 1 to 27, for use as a dietary supplement in a subject.

### Claim 29

29) A dietary supplement comprising the composition according to any one of the preceding claims.

### Claim 30

30) The composition according to any one of the preceding claims for use in treating heavy metal poisoning in a subject.

### Claim 31 (depends on 30)

31) The composition for use according to claim 30, wherein said treating further comprises administering a further chelating agent.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

32) The composition according to any one of claims 1 to 29, for use in treating or preventing a neurodegenerative disorder in a subject.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

33) The composition according to any one of claims 1 to 29, for use in treating or preventing cancer.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

34) A method of treating heavy metal poisoning in a subject, the method comprising administering to the subject a composition according to any one of claims 1 to 29.

### Claim 35 (depends on 34)

35) The method according to claim 34, the method further comprising administering to the subject a further chelating agent.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

36) A method of treating or preventing a neurodegenerative disorder in a subject, the method comprising administering to the subject a composition according to any one of claims 1 to 29.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

37) A method of treating or preventing cancer in a subject, the method comprising administering to the subject a composition according to any one of claims 1 to 29.

### Claim 38 (depends on 32, 36)

38) The composition for use according to claim 32 or the method according to claim 36, wherein the neurodegenerative disorder is selected from Alzheimer's disease and dementia.

### Claim 39 (depends on 28, 30, 31, 32, 33, 34, 35, 36, 37, 38)

39) The composition for use according to any one of claim 28, 30 to 33 or 38, or the method according to any one of claims 34 to 38, wherein the subject is a human.

### Claim 40 (depends on 28, 30, 31, 32, 33, 34, 35, 36, 37, 38)

40) The composition for use according to any one of claim 28, 30 to 33 or 38, or the method according to any one of claims 34 to 38, wherein the subject is an animal, optionally wherein the subject is cow, sheep, pig, poultry, cat or dog.

### Claim 41 (depends on 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

41) The composition for use according to any one of claims 28, 30 to 33 or 38 to 40, or the method according to any one of claims 34 to 40, wherein prior to administration of the composition to the subject, the level of heavy metal(s) are measured in the subject.

### Claim 42 (depends on 41)

42) The composition for use or the method according to claim 41, wherein excess level of heavy metal(s) are identified in the subject.

### Claim 43 (depends on 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

43) The composition for use or the method according to any one of claims 28, 30 to 33 or 38 to 42, or the method according to any one of claims 34 to 42, wherein the level of heavy metal(s) in the subject are assessed subsequent to administration of the composition to the subject.

### Claim 44 (depends on 43)

44) The composition for use or the method according to claim 43 wherein, upon identification of excess level of heavy metal(s) in the subject, said composition is re-administered to the subject.

### Claim 45 (depends on 43, 44)

45) The composition for use or the method according to claim 43 or claim 44 wherein, upon identification of a deficiency in one or more beneficial heavy metal(s) in the subject, corresponding heavy metal supplement is/are administered to the subject.

### Claim 46 (depends on 41, 42, 43, 44, 45)

46) The composition for use or the method according to any one of claims 41 to 45, wherein the level of heavy metal(s) in the subject are measured using a spectrometer.

### Claim 47 (depends on 46)

47) The composition for use or the method according to claim 46, wherein the spectrometer is a miniature spectrometer.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

48) A method for producing the composition according to any one of claims 1 to 29, the method comprising:
a) mixing the chelating agent with the extended surface biologically inert substrate; and
b) agitating the mixture.

### Claim 49 (depends on 48)

49) The method according to claim 48 wherein agitating the mixture comprises subjecting the mixture to cavitation.

### Claim 50 (depends on 48, 49)

50) The method according to claim 48 or claim 49, wherein agitating the mixture comprises subjecting the mixture to sonication.

### Claim 51 (depends on 50)

51) The method according to claim 50, wherein the sonication is ultrasonication.

### Claim 52 (depends on 51)

52) The method according to claim 51, wherein the ultrasonication is Barbell Horn ultrasonication.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

53) A method for producing the composition according to any one of claims 1 to 29, the method comprising synthesising the extended surface biologically inert substrate in the presence of the chelating agent.

### Claim 54 (depends on 53)

54) The method according to claim 53, wherein the extended surface biologically inert substrate is clinoptinolite.

### Claim 55 (depends on 53, 54)

55) The method according to claim 53 or claim 54, wherein the chelating agent is melanin.

### Claim 56 (depends on 55)

56) The method according to claim 55, the method comprising:
a) mixing melanin with an alkaline source, a silica source, and an alumina source; and
b) applying hydrothermal conditions to the mixture.
